Atrial Fibrillation Research

Published Online: Tuesday, January 14, 2014
Follow Pharmacy_Times:
Chris Cannon, MD, FACC, discusses 3 research papers on atrial fibrillation in this video produced by the American College of Cardiology.

Related Articles
Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals’ rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug’s safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.
The FDA has approved Daiichi Sankyo’s anti-clotting drug, edoxaban (Savaysa), as a once-daily treatment to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Roughly 50 million Americans take daily low-dose aspirin for cardioprevention, as it is generally perceived as a safe, effective, and inexpensive OTC preventive medication for cardiovascular disease. For patients who have nonvalvular atrial fibrillation, many guidelines recommend aspirin as thromboprophylaxis among those who are not considered to be high risk.
With proper treatment, individuals with atrial fibrillation can live normal and active lives.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$